BioPharma Credit Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	129.89	122.18	108.45	182.31	84.96
Other Adjustments	-17.55	0.09	23.95	-5.92	23.77
Change in Receivables	-21.8	-11.48	-0.48	-9.83	-9.8
Changes in Accounts Payable	0.56	1.12	-8.74	17.71	-2.49
Changes in Other Operating Activities	91.1	111.91	123.18	184.28	96.44
Operating Cash Flow	91.1	111.91	123.18	184.28	96.44
Operating Cash Flow Growth	-18.60%	-9.15%	-33.15%	91.09%	66.06%
Purchases of Investments	-83.75	-	-36.66	-100	-187.14
Proceeds from Sale of Investments	161.23	39.07	35	148.19	92.32
Investing Cash Flow	77.48	39.07	-1.66	48.19	-94.82
Repurchase of Common Stock	-51.27	-105.75	-17.22	-50.09	-
Net Common Stock Issued (Repurchased)	-51.27	-105.75	-17.22	-50.09	-
Common Dividends Paid	-110.38	-174.66	-89.77	-156.54	-100.16
Financing Cash Flow	-161.65	-280.42	-106.99	-206.62	-100.16
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.04	-0	-0.01	-0.03	-0.02
Net Cash Flow	6.93	-129.43	14.53	25.85	-98.54